文献速递糖尿病肥胖与代谢综合征

糖尿病前期患者体重减轻诱导缓解的机制:随机对照多中心糖尿病前期生活方式干预研究(PLIS)的事后分析

Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS).
PubMed 文献 · Lancet Diabetes Endocrinol · 2023-09-25

该研究为PLIS随机对照多中心试验的事后分析,纳入体重减轻≥5%的糖尿病前期患者,比较达到糖尿病前期缓解者与未缓解者的胰岛素敏感性、胰岛素分泌、内脏脂肪及肝内脂质变化,并在DPP研究中验证。结果显示缓解者胰岛素敏感性和内脏脂肪改善更明显,胰岛素分泌无差异,肝内脂质下降无组间差异。

要点

  • 糖尿病前期缓解者较未缓解者年轻(平均55.6岁 vs 60.4岁,p<0.0001)。
  • 缓解者全身胰岛素敏感性增加更多,胰岛素分泌无组间差异。
  • 缓解者内脏脂肪下降更多,肝内脂质下降无组间差异。

核心结论

  • 与2型糖尿病缓解不同,糖尿病前期缓解的特征是胰岛素敏感性改善和内脏脂肪减少。
  • 作者提出糖尿病前期缓解的概念,并建议将糖尿病前期缓解作为糖尿病前期个体的主要治疗目标。

研究设计与样本

  • PLIS为随机对照多中心研究,2012年3月1日至2016年8月31日在德国8个临床研究中心招募参与者,随机分配接受对照干预、标准生活方式干预(基于DPP)或强化生活方式干预12个月。
  • 本分析为预设事后分析,仅纳入随机分配至生活方式干预或安慰剂且体重减轻至少5%的参与者,并在DPP研究参与者中验证。
  • DPP研究于1996年7月31日至1999年5月18日在美国23个临床研究中心招募参与者,随机分配接受标准生活方式干预、二甲双胍或安慰剂。
  • PLIS纳入298例体重减轻≥5%者,其中缓解者128例(43%),未缓解者170例(57%);DPP验证队列纳入683例体重减轻≥5%者,其中缓解者132例(19%),未缓解者551例(81%)。

主要发现

  • PLIS中缓解者较未缓解者年轻(平均年龄55.6岁[SD 9.9] vs 60.4岁[8.6];p<0.0001)。
  • BMI下降在缓解者与未缓解者间相似(缓解者基线均值32.4 kg/m2[SD 5.6]至12个月均值29.0 kg/m2[4.9] vs 未缓解者32.1 kg/m2[5.9]至29.2 kg/m2[5.4];p=0.86)。
  • 全身胰岛素敏感性在缓解者中增加更多(缓解者基线均值291 mL/(min×m2)[SD 60]至12个月均值378 mL/(min×m2)[56] vs 未缓解者278 mL/(min×m2)[62]至323 mL/(min×m2)[66];p<0.0001),而胰岛素分泌在组内随时间及组间均无差异(缓解者基线均值175 pmol/mmol[SD 64]至12个月均值163.7 pmol/mmol[60.6] vs 未缓解者158.0 pmol/mmol[55.6]至154.1 pmol/mmol[56.2];p=0.46)。
  • 肝内脂质在两组均下降,组间无差异(缓解者基线均值10.1%[SD 8.7]至12个月均值3.5%[3.9] vs 未缓解者10.3%[8.1]至4.2%[4.2];p=0.34);内脏脂肪在缓解者中下降更多(缓解者基线均值6.2 L[SD 2.9]至12个月均值4.1 L[2.3] vs 未缓解者5.7 L[2.3]至4.5 L[2.2];p=0.0003)。
  • 缓解者干预结束后2年内发生2型糖尿病的风险较未缓解者低73%。

关键数值与推荐

  • 缓解定义为12个月生活方式干预或安慰剂或对照干预后恢复至正常空腹血糖(<5.6 mmol/L)、正常糖耐量(<7.8 mmol/L)且HbA1c低于39 mmol/mol。
  • 未缓解定义为空腹血糖、2小时血糖或HbA1c高于上述阈值。

临床怎么用

  • 作者提出糖尿病前期缓解的概念,并建议将糖尿病前期缓解作为糖尿病前期个体的主要治疗目标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Remission of type 2 diabetes can occur as a result of weight loss and is characterised by liver fat and pancreas fat reduction and recovered insulin secretion. In this analysis, we aimed to investigate the mechanisms of weight loss- induced remission in people with prediabetes. METHODS: In this prespecified post-hoc analysis, weight loss-induced resolution of prediabetes in the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS) was assessed, and the results were validated against participants from the Diabetes Prevention Program (DPP) study. For PLIS, between March 1, 2012, and Aug 31, 2016, participants were recruited from eight clinical study centres (including seven university hospitals) in Germany and randomly assigned to receive either a control intervention, a standard lifestyle intervention (ie, DPP-based intervention), or an intensified lifestyle intervention for 12 months. For DPP, participants were recruited from 23 clinical study centres in the USA between July 31, 1996, and May 18, 1999, and randomly assigned to receive either a standard lifestyle intervention, metformin, or placebo. In both PLIS and DPP, only participants who were randomly assigned to receive lifestyle intervention or placebo and who lost at least 5% of their bodyweight were included in this analysis. Responders were defined as people who returned to normal fasting plasma glucose (FPG; <5·6 mmol/L), normal glucose tolerance (<7·8 mmol/L), and HbA1c less than 39 mmol/mol after 12 months of lifestyle intervention or placebo or control intervention. Non-responders were defined as people who had FPG, 2 h glucose, or HbA1c more than these thresholds. The main outcomes for this analysis were insulin sensitivity, insulin secretion, visceral adipose tissue (VAT), and intrahepatic lipid content (IHL) and were evaluated via linear mixed models. FINDINGS: Of 1160 participants recruited to PLIS, 298 (25·7%) had weight loss of 5% or more of their bodyweight at baseline. 128 (43%) of 298 participants were responders and 170 (57%) were non-responders. Responders were younger than non-responders (mean age 55·6 years [SD 9·9] vs 60·4 years [8·6]; p<0·0001). The DPP validation cohort included 683 participants who lost at least 5% of their bodyweight at baseline. Of these, 132 (19%) were responders and 551 (81%) were non-responders. In PLIS, BMI reduction was similar between responders and non-responders (responders mean at baseline 32·4 kg/m2 [SD 5·6] to mean at 12 months 29·0 kg/m2 [4·9] vs non-responders 32·1 kg/m2 [5·9] to 29·2 kg/m2 [5·4]; p=0·86). However, whole-body insulin sensitivity increased more in responders than in non-responders (mean at baseline 291 mL/[min × m2], SD 60 to mean at 12 months 378 mL/[min × m2], 56 vs 278 mL/[min × m2], 62, to 323 mL/[min × m2], 66; p<0·0001), whereas insulin secretion did not differ within groups over time or between groups (responders mean at baseline 175 pmol/mmol [SD 64] to mean at 12 months 163·7 pmol/mmol [60·6] vs non-responders 158·0 pmol/mmol [55·6] to 154·1 pmol/mmol [56·2]; p=0·46). IHL decreased in both groups, without a difference between groups (responders mean at baseline 10·1% [SD 8·7] to mean at 12 months 3·5% [3·9] vs non-responders 10·3% [8·1] to 4·2% [4·2]; p=0·34); however, VAT decreased more in responders than in non-responders (mean at baseline 6·2 L [SD 2·9] to mean at 12 months 4·1 L [2·3] vs 5·7 L [2·3] to 4·5 L [2·2]; p=0·0003). Responders had a 73% lower risk of developing type 2 diabetes than non-responders in the 2 years after the intervention ended. INTERPRETATION: By contrast to remission of type 2 diabetes, resolution of prediabetes was characterised by an improvement in insulin sensitivity and reduced VAT. Because return to normal glucose regulation (NGR) prevents development of type 2 diabetes, we propose the concept of remission of prediabetes in analogy to type 2 diabetes. We suggest that remission of prediabetes should be the primary therapeutic aim in individuals with prediabetes. FUNDING: German Federal Ministry for Education and Research via the German Center for Diabetes Research; the Ministry of Science, Research and the Arts Baden-Württemberg; the Helmholtz Association and Helmholtz Munich; the Cluster of Excellence Controlling Microbes to Fight Infections; and the German Research Foundation.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Sandforth A, von Schwartzenberg RJ, Arreola EV, et al. Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS). Lancet Diabetes Endocrinol. 2023. PMID: 37769677. doi:10.1016/S2213-8587(23)00235-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。